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odern psychopharmacology began in the 1950s
with the discovery of chlorpromazine and later haloperi-
dol,drugs that were mainly discovered by serendipity.A
vast number of similar phenothiazine- and butyrophe-
none-structured “me too” drugs with similar receptor
binding profiles and therapeutic benefit were developed
in the subsequent years (the so-called typical antipsy-
chotics).The first real alternative to these drugs,in terms
of mode of action and therapeutic outcome, became
available with the introduction of clozapine (an atypical
antipsychotic).The discovery of clozapine,and drugs like
it, led to the dopamine hypothesis of schizophrenia,
1
which had a high impact on the search for neurotrans-
mitter functions.However,the pathophysiology of schiz-
ophrenic symptoms and the related mechanism of action
of antipsychotics could not be fully explained.It became
increasingly evident that schizophrenia is both a com-
plex disease,in which numerous factors contribute to the
symptomatology, and a heterogeneous disease, most
probably resulting from many different pathological
causes. To underline this, no convincing evidence of
abnormal biological findings valid for all or most of the
patients with schizophrenia could be found. However,
most clinical studies could demonstrate that antipsy-
chotics were an effective treatment in schizophrenia and
that they considerably ameliorated the outcome of the
disease.The disadvantage of these drugs are their major
side effects,such as parkinsonian symptoms,dyskinesia,
and akathisia, due to the extrapyramidal motor system,
and sometimes depressive effects.
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The typical antipsychotic drugs like chlorpromazine and
haloperidol were discovered by serendipity in the 1950s.
A number of so-called “me too” drugs with similar chem-
ical structures and modes of action were marketed in the
subsequent years. The first atypical antipsychotic, clozap-
ine, was an exception because it lacked some of the phar-
macological properties of the typical antipsychotics
related to the extrapyrimidal motor system. This unique
feature of clozapine significantly broadened understand-
ing of the mode of action of antipsychotics, and created
new hypotheses for schizophrenia. Hypothesis-orientated
development of new drugs was only recently initiated.
Abnormalities of the immune system in schizophrenia are
being increasingly discussed: shifts in the levels of T helper
cells subsets 1 and 2 (Th1 and Th2) have been observed,
and studies with risperidone and the cyclooxengenase
(COX2) inhibitor celecoxib as an add-on therapy have pro-
vided very promising results. The glutamate N-methyl-D-
aspartate (NMDA) receptors have also been investigated
in relation to neuropathological abnormalities in pre-
frontal areas of the brain of patients with schizophrenia.
This may lead to new technologies like artificial networks
related to the glutamate NMDA receptor system. New
molecular biological techniques used in pharmaco-
genomics and proteomics offer new and exciting direc-
tions for future drug developments.
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Current knowledge suggests that the antipsychotic effect
of the typical antipsychotics is mediated by the ability to
reduce mesolimbic dopaminergic activity, whereas the
side effects related to the extrapyramidal motor system
are caused by a decreased dopaminergic activity in the
nigrostriatal system.
2
The introduction of clozapine with its unique pharma-
cological profile pointed to various theories.The unique
effect of clozapine contributed to the relative prepon-
derance of clozapine in the mesolimbic system. Other
biochemical features have been related to its pharma-
cological profile. Clozapine has different affinities for
the different dopamine receptor subtypes.There are two
major types of dopamine receptor:D1 and D2 receptors.
The D1 receptor family includes D1 and D5, which are
positively coupled to G-proteins,whereas the three D2-
like receptors, D2,D 3, and D4, inhibit the G-protein
adenylate cyclase system. Clozapine has relatively
stronger effects on the D1 and D2 receptors than other
classic neuroleptics, which predominantly block the D2
receptors;o-benzamides like sulpiride and amisulpride
have a relatively strong effect on the D3 receptors.In the
case of clozapine,the ratio of D4 to D2 receptors is also
crucial. In the last few years, this limited thinking
focused on dopamine receptors has been abandoned in
favor of a broader approach including other neuro-
transmitter systems in neuronal circuits. Clozapine and
the new atypical antipsychotics also influence other neu-
rotransmitter systems,notably the serotonin (5-hydroxy-
tryptamine) 5-HT2A receptor, the α1 and α2 adrenergic
receptors,and sometimes the histaminic and muscarinic
receptors.
Since biochemical and molecular genetic studies have
failed to prove the dopamine hypothesis of schizophre-
nia and the broader view of other related neurocircuits,
other theories of schizophrenia have been hypothesized
(Figure 1).
3
Immunology and schizophrenia
In addition to hypotheses surrounding the classic neu-
rotransmitters, the glutamate hypothesis and the
immunological and neurodevelopmental theories for
schizophrenia came into play. Abnormalities of the
immune system are being increasingly discussed, and
there is much evidence that abnormalities of the
immune system play a major role in the development of
schizophrenia.Links with seasonality of birth,influenza
epidemics during gestation,pathological findings in cere-
brospinal fluid (CSF),and genetic findings on the chro-
mosomes with genes for immune response have been
reported.We found an imbalance of the T helper subset 1
and 2 immune cells,Th1 and Th2,in schizophrenia.
4Th2
preponderance leads to a higher expression of humoral
responses, which can be measured by the immunoglob-
ulins,interleukin (IL) 4,and IL-6.The Th1 cells respon-
sible for cellular response are related to IL-2 and IL-γ,
which have lower levels in blood and CSF in schizo-
phrenia (Table I). In relation to this theory, new treat-
ment strategies may soon be available for patients with
schizophrenia.
The question is whether it is possible to produce a reduc-
tion in the Th2 shift and an induction of the Th1 shift in
schizophrenia. One of the current treatments for dis-
eases of the immune system, like in rheumatology, is
cyclooxygenase-2 (COX2) inhibitors.Interestingly,there
is a negative correlation between the occurrence of schiz-
ophrenia and rheumatoid arthritis.
5 COX2 enhances pro-
duction of IL-6
6 and IL-10
7 via prostaglandin E2,and inhi-
bition of COX2 leads to a decrease in production of
IL-10.
On the basis of these theories, we carried out a clinical
trial with a COX2 inhibitor,celecoxib,as an add-on ther-
apy versus placebo.
8 In this double-blind, placebo-con-
trolled, randomized trial with a parallel-group design,
patients were treated with risperidone 2 to 6 mg/day plus
celecoxib (400 mg/day) or risperidone 2 to 6 mg/day plus
placebo. Twenty-five patients were included in each
group. It was shown that the add-on therapy of COX2
inhibition significantly reduced the total score on the
Positive and Negative Syndrome Scale (PANSS) com-
pared with the risperidone–placebo group.Simultaneous
measurement of plasma levels of risperidone did not
show a difference. Further studies in a greater number
of patients,which are currently underway,will hopefully
support these preliminary results. Figure 1. Historical development of major antipsychotic substances.
3
Antipsychotic therapy: historical perspective
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ZiprasidoneGlutamate and schizophrenia
Possible links between abnormalities of the immune system
and another neurotransmitter system,the glutamate system
may exist,according to animal models of autoimmune dis-
eases. Transgenic mice lacking IL-2 are susceptible to
autoimmune diseases.Cytokines can influence the activity
of the glutamate system.
9The glutamate system is closely
connected to dopaminergic and serotonergic neurons.
Hypofunction of the N-methyl-D-aspartate (NMDA)
receptor leads to increased dopaminergic activity in the
frontal cortex.The NMDA glutamate hypothesis offers a
possible link between the various theories surrounding the
immune system and the hypothesis related to neurotrans-
mitters.The growing importance of amino acid transmitters
like glutamate was recognized from neuroimaging studies
and neuro-pathological findings showing an involvement
of the cerebral cortex (in which the major neurons are glu-
tamatergic) in the neuropathology of schizophrenia.
Further support came from the psychotomimetic effects
of the NMDA-receptor antagonists phenylcyclidine
(PCP), dizocilpine (MK-801), and ketamine.The theo-
ries focused on these NMDA receptors because of the
psychomimetic effects of NMDA antagonists. Most
notably, PCP and ketamine can induce symptoms
related to schizophrenic symptomatology in healthy
human subjects.Positive symptoms like grandiose para-
noid delusions,bizarre ideation,and hallucinations have
been described,as have negative symptoms like blunted
affect and psychomotor retardation. Furthermore, cog-
nitive deficits related to circuits in the frontal cortex
have been observed, like distractibility, reduced verbal
fluency,and working memory deficits.Cognitive deficits
related to temporal hippocampal circuits have also been
reported, like the disruption of new learning and
reduced prepulse inhibition of the startle response.
In the so-called revised dopamine hypothesis, Carlsson
underlined the central role of glutamate–γ-aminobutyric
acid (GABA) in neuronal circuits,which are closely con-
nected to other neurotransmitters,eg,dopamine,norepi-
nephrine,serotonin,acetylcholine,and glycine.The gluta-
mate receptor system offers multiple targets for
pathogenesis and pathophysiology in schizophrenia,and
is rather complex.Four classes of glutamate receptors,the
NMDA,the amino-3-hydroxy-5-methyl-4-isoxazole pro-
pionic acid (AMPA),the kainate,and the metabotropic
receptors, each of which has a wide variety of subunits,
form various receptor combinations,and can be differen-
tiated on this basis (Figure 2).
10These NMDA antagonis-
tic drugs lead to NMDA receptor hypofunction,which is
due to the connections with the other neurotransmitter
systems,producing an excessive release of excitatory trans-
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Figure 2. Glutamate receptor subunits and binding sites. AMPA, amino-
3-hydroxy-5-methyl-4-isoxazole propionic acid; PCP, phencycli-
dine; NMDA, N-methyl-D-aspartate.
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Table I. Markers of Th1/Th2 responses in schizophrenia. Alterations of
immunologic parameters in schizophrenic patients: the Th2 shift.
4
CSF, cerebrospinal fluid; IFN-γ, interferon gamma; IgE,
immunoglobulin E; IgG, immunoglobulin G; IL, interleukin; sIL, sol-
uble interleukin; TGF, transforming growth factor; Th1, T helper
cell subset 1; Th2, T helper cell subset 2. 
Reproduced from reference 4: Schwarz MJ, Müller N, Riedel M, Ackenheil M. The Th2
hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused
by immune mechanisms. Med Hypotheses. 2001;56:483-486. Copyright © 2001,
Harcourt Publishers Ltd.
Site of cytokine  Th1 Th2
expression
In vitro production IFN-γ↓ ↓ IL-10 ↑
IL-2 ↓↓ IL-3 ↑
Peripheral levels IFN-γ↔ IgE ↑↑
IL-2 ↔ Antibodies against
several antigens ↑↑
sIL-2R ↑↑ IL-6 ↑↑
After remission:
IL-6 ↓↓
CSF levels IL-2  ↓↑ IgG ↑
IFN-γ↓ IL-4 ↑
TGF-β1 ↔
TGF-β2 ↔
Hypothesis  A Th2 shift in schizophrenia with
predominant negative symptoms
and treatment resistanceTreatment of schizophrenia - Ackenheil and Weber Dialogues in Clinical Neuroscience - Vol 4 . No.4 . 2002
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mitters in the cerebral cortex,and with other transmitters
like dopamine.It is of interest that these psychotomimetic
effects are only seen in adults,and not in children or young
adolescents.
11 It is therefore postulated that the effects
depend on the maturation of the brain and that an intact
wiring of all neurons is necessary to produce such effects,
and that this is only finalized during adolescence.
Animal experiments show that,depending on the sever-
ity or grade of NMDA receptor hypofunction, the first
psychotomimetic effects occur later than the neurotoxic
effects, which lead to neurodegeneration of cells.
Chronic treatment with certain drugs like olanzapine,
clozapine, lamotrigine,α2-adrenergic agonists, and per-
haps antimuscarinic agents could prevent these neuro-
toxic effects.The NMDA receptor is, in addition to the
L-glutamic acid–responsive recognition site, also mod-
ulated via the glycine-B receptor, indicating that the
inhibitory amino acid glycine could have antipsychotic
properties.Animal models have been developed to test
antipsychotic agents on the basis of the reduced prepulse
inhibition of the startle response,which can be observed
in schizophrenic patients.
12 Prepulse inhibition is used as
a model for attentional processes, and NMDA antago-
nists can disrupt prepulse inhibition.This disruption in
prepulse inhibition can be prevented by atypical antipsy-
chotics like clozapine,risperidone,quetiapine,and olan-
zapine.
13 Most recently,artificial neuronal networks have
been cultured on microelectrode arrays to evaluate new
drugs in a very effective manner. For example, primary
embryonic rat spine neurons have been cultured on
microelectrode arrays.These neuronal networks display
in vitro complex spatiotemporal spike and burst pat-
terns, which are highly sensitive to their chemical envi-
ronment and allow precise pharmacological manipula-
tions free of homeostatic interference.
14 Preliminary
results have been reported with the cannabinoid ago-
nists anandamide and methanandamide.Anandamide
and methanandamide reversibly inhibited spike and
burst production in these neuronal networks. Similarly,
a dose-dependent stimulatory effect of glutamate on
extracellular neuronal potentials has been recorded.
First, an increased frequency of spikes was observed
with serial elevations of the glutamate concentration;
exposure to higher levels resulted in functional neuro-
toxicity.This new methodology allows a very rapid test-
ing of new drugs, to determine which interfere with the
glutamate system. In this way, complex and expensive
animal experiments can be drastically reduced.
Future directions
The reported theories can be tested in humans with new
molecular biological techniques related to the pharma-
cogenetics and pharmacogenomics of drugs.
15According
to the recently completed draft sequence, the human
genome comprises about 30 000 to 35 000 genes.At least
half of them are expressed in the brain.These could be
targets for psychotropic drugs and therefore be related
to the pathophysiology of mental disorders.An impor-
tant challenge for pharmacogenetic studies is to choose
candidate genes that may be relevant to drug response.
There are three ways to achieve this goal:
• Knowing the mechanism of action of the drugs.
• Identifying the genes that are switched on or off,using
expression studies.
• Identifying the susceptibility loci for the psychiatric
disorders,using linkage or association studies.
Since the genes are expressed by messenger RNA and
this is translated into proteins that will determine the
functioning of the brain,the method of proteomics offers
another route to new drug targets.
16The essence of pro-
teomics is the identification of proteins that are uniquely
expressed in brain tissues.Protein expression profiles in
disease are compared with known disease tissues.This
can be done in postmortem brains,CSF,and peripheral
blood cells like lymphocytes. This can be a powerful
approach to overcome the problem of genome-based
technologies that do not consider differences between
DNA structure,gene expression,and the functions of the
proteins.Preliminary results have already been reported,
but so far in an inconsistent manner.
17,18The major diffi-
culty is the collection of representative tissue samples.
Most sample brain tissue comes from postmortem brains
and suicide victims,but it must be representative so as to
avoid pitfalls due to different times after death and dif-
ferent unknown treatments.
With the help of pharmacogenomics and proteomics,an
individualized therapy can be offered to each patient,to
overcome the problem of heterogeneity of the disease
and heterogeneity of therapeutic response.❏Pharmacological aspects
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Desarrollos en la terapia antipsicótica 
basados en las hipótesis para la 
esquizofrenia
Los fármacos antipsicóticos típicos como la clorpro-
mazina y el haloperidol fueron descubiertos en
forma casual en la década de 1950. Un número de
fármacos de los así llamados “yo también” con
estructuras químicas y mecanismos de acción simi-
lares fueron puestos en el mercado en los años
siguientes. El primer antipsicótico atípico, la cloza-
pina, fue una excepción por el hecho de carecer de
algunas de las propiedades farmacológicas de los
antipsicóticos típicos relacionadas con el sistema
motor extrapiramidal. Esta característica singular de
la clozapina amplió significativamente la compren-
sión acerca del mecanismo de acción de los antipsi-
cóticos y dio origen a nuevas hipótesis para la esqui-
zofrenia. Sólo recientemente se ha iniciado un
desarrollo de nuevos fármacos en base a dichas
hipótesis. Las anormalidades del sistema inmune en
la esquizofrenia están siendo cada vez más discu-
tidas: se han observado cambios en los niveles de
los subtipos 1 y 2 de las células T helper (Th1 y Th2),
y se han obtenido resultados muy promisorios en
estudios con risperidona y celecoxib, un inhibidor
de la ciclooxigenasa (COX2), como una terapia com-
binada. Los receptores de glutamato del tipo
NMDA (N-metil-D-aspartato) también han sido
investigados en relación con las alteraciones neu-
ropatológicas en las áreas prefrontales del cerebro
en pacientes con esquizofrenia. Esto puede condu-
cir a nuevas tecnologías como las redes artificiales
que se relacionan con el sistema receptor de gluta-
mato NMDA. Las nuevas técnicas de biología mole-
cular utilizadas en farmacogenómica y proteómica
ofrecen nuevas y excitantes perspectivas para los
futuros desarrollos de fármacos.
Avancées dans le traitement des psychoses et
implications relatives aux hypothèses sur la
schizophrénie
Les neuroleptiques typiques tels que la chlorproma-
zine et l’halopéridol ont été découverts fortuite-
ment dans les années 1950. Un certain nombre de
médicaments appelés « me too (moi aussi) » de
même structure chimique et de même mode d’ac-
tion ont été mis sur le marché au cours des années
suivantes. Le premier antipsychotique atypique, la
clozapine, était une exception parce qu’il lui man-
quait quelques propriétés pharmacologiques des
antipsychotiques classiques liées au système moteur
extrapyramidal. Cette caractéristique unique de la
clozapine a élargi de façon significative la compré-
hension du mode d’action des neuroleptiques, et a
permis de nouvelles hypothèses sur la schizophré-
nie. Le développement de nouveaux médicaments
basé sur des hypothèses pharmacologiques a débuté
récemment seulement. Des anomalies du système
immunitaire au cours de la schizophrénie sont de
plus en plus évoquées : des déviations dans les
niveaux des sous-populations 1 et 2 (Th1 et Th2) de
cellules T amplificatrices ont été observées, et des
études de traitements additionnels avec la rispéri-
done et un inhibiteur de la cyclooxygénase (COX2),
le célécoxib, ont fourni des résultats très promet-
teurs. Les rapports entre récepteurs du glutamate N-
méthyl-D-aspartate (NMDA) et les anomalies neuro-
pathologiques des aires préfrontales du cerveau de
patients atteints de schizophrénie ont également
été étudiés. Ceci pourrait conduire à de nouvelles
technologies comme les réseaux artificiels liés au sys-
tème des récepteurs du glutamate NMDA. Les nou-
velles techniques de biologie moléculaire utilisées
en pharmacogénomique et protéomique offrent
des voies nouvelles et passionnantes pour le déve-
loppement de futurs médicaments.Treatment of schizophrenia - Ackenheil and Weber Dialogues in Clinical Neuroscience - Vol 4 . No.4 . 2002
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